Calculating The Fair Value Of Yunnan Baiyao Group Co.,Ltd (SZSE:000538)
Key Insights
- Yunnan Baiyao GroupLtd's estimated fair value is CN¥53.64 based on 2 Stage Free Cash Flow to Equity
- Yunnan Baiyao GroupLtd's CN¥61.00 share price indicates it is trading at similar levels as its fair value estimate
- Analyst price target for 000538 is CN¥64.58, which is 20% above our fair value estimate
How far off is Yunnan Baiyao Group Co.,Ltd (SZSE:000538) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. This will be done using the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
Check out our latest analysis for Yunnan Baiyao GroupLtd
The Method
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥4.83b | CN¥5.46b | CN¥5.51b | CN¥4.98b | CN¥4.70b | CN¥4.56b | CN¥4.50b | CN¥4.49b | CN¥4.53b | CN¥4.60b |
Growth Rate Estimate Source | Analyst x2 | Analyst x2 | Analyst x2 | Analyst x1 | Est @ -5.61% | Est @ -3.07% | Est @ -1.30% | Est @ -0.05% | Est @ 0.82% | Est @ 1.43% |
Present Value (CN¥, Millions) Discounted @ 6.8% | CN¥4.5k | CN¥4.8k | CN¥4.5k | CN¥3.8k | CN¥3.4k | CN¥3.1k | CN¥2.8k | CN¥2.6k | CN¥2.5k | CN¥2.4k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥34b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.8%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥4.6b× (1 + 2.9%) ÷ (6.8%– 2.9%) = CN¥119b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥119b÷ ( 1 + 6.8%)10= CN¥61b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is CN¥96b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of CN¥61.0, the company appears around fair value at the time of writing. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Yunnan Baiyao GroupLtd as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Yunnan Baiyao GroupLtd
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- Dividend is in the top 25% of dividend payers in the market.
- No major weaknesses identified for 000538.
- Annual earnings are forecast to grow for the next 3 years.
- Good value based on P/E ratio compared to estimated Fair P/E ratio.
- Dividends are not covered by cash flow.
- Annual earnings are forecast to grow slower than the Chinese market.
Moving On:
Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Yunnan Baiyao GroupLtd, we've put together three essential factors you should explore:
- Risks: Take risks, for example - Yunnan Baiyao GroupLtd has 1 warning sign we think you should be aware of.
- Future Earnings: How does 000538's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:000538
Yunnan Baiyao GroupLtd
Engages in the pharmaceutical business in China, Southeast Asia, Europe, the United States, Japan, and internationally.
Flawless balance sheet established dividend payer.